Los Angeles, Calif. – Investigators from the UCLA Health Jonsson Comprehensive Cancer Center have identified a protein, called UCHL1, in highly aggressive neuroendocrine carcinomas and neuroblastoma that could potentially be used as a molecular biomarker for diagnosing these cancers and predicting and monitoring responses to therapy. The team also found that using a UCHL1 inhibitor,...
Latest News
Charleston, SC – When Nancy Klauber-DeMore, M.D., began studying secreted frizzled-related protein 2, or SFRP2, it was as a breast cancer researcher and surgeon. Since she first showed in 2008 that the protein is involved in tumor growth and angiogenesis – the growth of new blood vessels to feed the...
Washington, DC — A team of U.S. investigators led by neuroscientists at Georgetown University Medical Center (GUMC) are steadily uncovering the role that amyloid precursor protein (APP) – the protein implicated in development of Alzheimer’s disease – plays in normal brain function. In the June 10 issue of the Journal...
CINCINNATI — Researchers at the University of Cincinnati (UC) have discovered a protein in the lungs that can help in determining progression of the rare lung disease Idiopathic Pulmonary Fibrosis (IPF). Researchers say the protein—Serum surfactant protein A—is superior to other IPF predictors and could lead to better decisions about...
PORTLAND, Oregon — New research from Oregon Health & Science University could one day lead to therapies that prevent or treat diseases and infections tied to a protein that’s found in all human cells. A study published today in the journal Molecular Cell describes how the protein ubiquitin is modified during a bacterial infection....
RICHLAND, Wash. — Doctors have nearly a dozen new targeted drugs to treat patients with acute myeloid leukemia, or AML, yet three of four patients still die within five years. Some patients succumb within just a month or two, despite the battery of drugs used to treat the aggressive blood...
DUBLIN, Ireland — Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced the publication related to the mechanism of action, pharmacological characteristics, and clinical utility of birtamimab, a potential best-in-class anti-amyloid treatment for AL amyloidosis. The...
BUFFALO, NY- February 7, 2024 – A new research paper was published in Aging Volume 16, Issue 2, entitled, “PROX1 interaction with α-SMA-rich cancer-associated fibroblasts facilitates colorectal cancer progression and correlates with poor clinical outcomes and therapeutic resistance.” The tumor microenvironment (TME) plays a vital role in tumor progression through...
TAMPA, Fla. — Psilera, a leading biopharmaceutical company focused on developing novel treatments for neurological disorders, is pleased to announce the selection of behavioral variant frontotemporal dementia (bvFTD) as the lead indication for its groundbreaking drug candidate, PSIL-006. This devastating form of early-onset dementia currently lacks approved treatments to manage symptoms...
SOUTH PLAINFIELD, N.J. – PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that both the United States Food and Drug Administration (FDA) and European Commission (EC) have granted Orphan Drug Designation (ODD) for PTC923 for the treatment of patients with hyperphenylalaninemia. Phenylketonuria (PKU) accounts for 98% of all hyperphenylalaninemia cases and is a metabolic condition that...